{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:16:52Z","timestamp":1788859012635,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.farma.2024.04.006","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:56:16Z","timestamp":1716494176000},"page":"265-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Perceived quality of life by patients with immune-mediated inflammatory diseases treated with biological therapies. SACVINFA study"],"prefix":"10.1016","volume":"48","author":[{"given":"Esther","family":"Chamorro-de-Vega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Fern\u00e1ndez-Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Hern\u00e1ndez-Muniesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Romero-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araceli","family":"Casado-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Morell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara","family":"\u00dabeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantza","family":"Ais-Larisgoitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lobato-Matilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Escudero-Vilaplana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2024.04.006_bb0005","article-title":"Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019","volume":"64","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.farma.2024.04.006_bb0010","article-title":"Prevalence of ten Immune-mediated inflammatory diseases (IMID) in Spain","volume":"93","author":"Puig","year":"2019","journal-title":"Rev Esp Salud Publica"},{"key":"10.1016\/j.farma.2024.04.006_bb0015","author":"Instituto Nacional de Estad\u00edstica"},{"key":"10.1016\/j.farma.2024.04.006_bb0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3899\/jrheum.110908","article-title":"Summing up: quality of life in chronic immune-mediated inflammatory diseases","volume":"88","author":"Bernstein","year":"2011","journal-title":"J Rheumatol Suppl"},{"issue":"5","key":"10.1016\/j.farma.2024.04.006_bb0025","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3899\/jrheum.130797","article-title":"Depression and anxiety in psoriatic disease: prevalence and associated factors","volume":"41","author":"McDonough","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.farma.2024.04.006_bb0030","author":"Ad\u00e1n Civera"},{"key":"10.1016\/j.farma.2024.04.006_bb0035","author":"EuroQol Research Foundation"},{"issue":"12","key":"10.1016\/j.farma.2024.04.006_bb0040","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1111\/jcpt.13742","article-title":"Evaluation of the hospital care quality perceived by patients with immune-mediated inflammatory diseases from the pharmacy service. SACVINFA study","volume":"47","author":"Ram\u00edrez","year":"2022","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"10.1016\/j.farma.2024.04.006_bb0045","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol--a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"issue":"5","key":"10.1016\/j.farma.2024.04.006_bb0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"issue":"5","key":"10.1016\/j.farma.2024.04.006_bb0055","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jval.2017.10.023","article-title":"Handling data quality issues to estimate the Spanish EQ-5D-5L value set using a hybrid interval regression approach","volume":"21","author":"Ramos-Go\u00f1i","year":"2018","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.farma.2024.04.006_bb0060","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/ard.2003.006296","article-title":"Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis","volume":"63","author":"McKenna","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.farma.2024.04.006_bb0065","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/1529-0131(200104)45:2<167::AID-ANR170>3.0.CO;2-X","article-title":"An English and Spanish quality of life measure for rheumatoid arthritis","volume":"45","author":"Danao","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.farma.2024.04.006_bb0070","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.62.1.20","article-title":"Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis","volume":"62","author":"Doward","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.farma.2024.04.006_bb0075","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000007670","article-title":"Validation of the Spanish version of the inflammatory bowel disease questionnaire on ulcerative colitis and Crohn's disease","volume":"60","author":"L\u00f3pez-Vivancos","year":"1999","journal-title":"Digestion"},{"issue":"3","key":"10.1016\/j.farma.2024.04.006_bb0080","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.farma.2024.04.006_bb0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"issue":"5","key":"10.1016\/j.farma.2024.04.006_bb0090","first-page":"767","article-title":"Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test","volume":"10","author":"Val Jim\u00e9nez","year":"1992","journal-title":"Aten Primaria"},{"issue":"9","key":"10.1016\/j.farma.2024.04.006_bb0095","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s11136-018-1877-5","article-title":"Validity of the EQ-5D-5L and reference norms for the Spanish population","volume":"27","author":"Hernandez","year":"2018","journal-title":"Qual Life Res"},{"issue":"51","key":"10.1016\/j.farma.2024.04.006_bb0100","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005652","article-title":"Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort","volume":"95","author":"Landi","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.farma.2024.04.006_bb0105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3109\/14397595.2015.1059983","article-title":"Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis; analysis of the IORRA database","volume":"26","author":"Hoshi","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"7","key":"10.1016\/j.farma.2024.04.006_bb0110","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s10067-015-3155-z","article-title":"Predictors of impaired quality of life in patients with rheumatic diseases","volume":"35","author":"Anyfanti","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.farma.2024.04.006_bb0115","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ad.2013.03.005","article-title":"Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: the VACAP study","volume":"104","author":"Daud\u00e9n","year":"2013","journal-title":"Actas Dermosifiliogr"},{"issue":"4","key":"10.1016\/j.farma.2024.04.006_bb0120","first-page":"364","article-title":"Fatigue in rheumatoid arthritis: association with severity of pain, disease activity and functional status","volume":"36","author":"Garip","year":"2011","journal-title":"Acta Reumatol Port"},{"issue":"6","key":"10.1016\/j.farma.2024.04.006_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198975","article-title":"The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases","volume":"13","author":"Enns","year":"2018","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.farma.2024.04.006_bb0130","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1176\/appi.psy.51.4.338","article-title":"Prevalence and determinants of psychiatric disorders in patients with rheumatoid arthritis","volume":"51","author":"Lok","year":"2010","journal-title":"Psychosomatics"},{"issue":"5","key":"10.1016\/j.farma.2024.04.006_bb0135","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1212\/WNL.0000000000006854","article-title":"Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders","volume":"92","author":"Whitehouse","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.farma.2024.04.006_bb0140","first-page":"288","article-title":"The TNF-alpha inhibitor etanercept as monotherapy in treatment-resistant depression - report of two cases","volume":"26","author":"Schmidt","year":"2014","journal-title":"Psychiatr Danub"},{"issue":"5","key":"10.1016\/j.farma.2024.04.006_bb0145","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3349\/ymj.2020.61.5.406","article-title":"Contribution of personality traits, psychological factors, and health-related quality of life to medication adherence in patients with rheumatoid arthritis","volume":"61","author":"Ko","year":"2020","journal-title":"Yonsei Med J"},{"issue":"2","key":"10.1016\/j.farma.2024.04.006_bb0150","first-page":"2312","article-title":"Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study","volume":"19","author":"Souza","year":"2021","journal-title":"Pharm Pract"},{"key":"10.1016\/j.farma.2024.04.006_bb0155","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2147\/PPA.S165101","article-title":"Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review","volume":"12","author":"Anghel","year":"2018","journal-title":"Patient Prefer Adherence"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T05:49:55Z","timestamp":1731649795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634324000564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1130634324000564"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2024.04.006","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perceived quality of life by patients with immune-mediated inflammatory diseases treated with biological therapies. SACVINFA study","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}